iData Insights

Vernalis Plc - Product Pipeline Review – 2015 Is Released

Press Release   •   Feb 10, 2016 13:59 IST

This report provides comprehensive information on the current therapeutic developmental pipeline of Vernalis plcs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Vernalis plc including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Vernalis plcs human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Vernalis plcs pipeline products Reasons to buy - Evaluate Vernalis plcs strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Vernalis plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Vernalis plcs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Vernalis plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vernalis plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Vernalis plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179162/vernalis-plc-product-pipeline-review-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179162/vernalis-plc-product-pipeline-review-2015

Table of Contents

Table of Contents 2


List of Tables 4


List of Figures 4


Vernalis Plc Snapshot 5


Vernalis Plc Overview 5


Key Information 5


Key Facts 5


Vernalis Plc - Research and Development Overview 6


Key Therapeutic Areas 6


Vernalis Plc - Pipeline Review 8


Pipeline Products by Stage of Development 8


Pipeline Products - Monotherapy 9


Pipeline Products - Partnered Products 10


Partnered Products/Combination Treatment Modalities 11


Pipeline Products - Out-Licensed Products 12


Out-Licensed Products/Combination Treatment Modalities 13


Vernalis Plc - Pipeline Products Glance 14


Vernalis Plc - Clinical Stage Pipeline Products 14


Phase II Products/Combination Treatment Modalities 14


Vernalis Plc - Early Stage Pipeline Products 15


Preclinical Products/Combination Treatment Modalities 15


Discovery Products/Combination Treatment Modalities 16


Vernalis Plc - Unknown Stage Pipeline Products 17


Unknown Products/Combination Treatment Modalities 17


Vernalis Plc - Drug Profiles 18


V-81444 18


Product Description 18


Mechanism of Action 18


R&D Progress 18


CCP-05 19


Product Description 19


Mechanism of Action 19


R&D Progress 19


CCP-06 20


Product Description 20


Mechanism of Action 20


R&D Progress 20


V-158411 21


Product Description 21


Mechanism of Action 21


R&D Progress 21


vipadenant 22


Product Description 22


Mechanism of Action 22


R&D Progress 22


Small Molecule to Inhibit Chk1 for Cancer 23


Product Description 23


Mechanism of Action 23


R&D Progress 23


CCP-07 24


Product Description 24


Mechanism of Action 24


R&D Progress 24


CCP-08 25


Product Description 25


Mechanism of Action 25


R&D Progress 25


Vernalis Plc - Pipeline Analysis 26


Vernalis Plc - Pipeline Products by Target 26


Vernalis Plc - Pipeline Products by Route of Administration 27


Vernalis Plc - Pipeline Products by Molecule Type 28


Vernalis Plc - Pipeline Products by Mechanism of Action 29


Vernalis Plc - Recent Pipeline Updates 30


Vernalis Plc - Dormant Projects 32


Vernalis Plc - Discontinued Pipeline Products 33


Discontinued Pipeline Product Profiles 33


alfadolone 33


indantadol 33


marimastat 33


solimastat 33


V-1003 33


V-158866 34


vipadenant 34


Vernalis Plc - Company Statement 35


Vernalis Plc - Locations And Subsidiaries 37


Head Office 37


Other Locations & Subsidiaries 37


Appendix 38


Methodology 38


Coverage 38


Secondary Research 38


Primary Research 38


Expert Panel Validation 38


Contact Us 38


Disclaimer 39" width="80" height="40" />Table of Contents


Table of Contents 2


List of Tables 4


List of Figures 4


Vernalis Plc Snapshot 5


Vernalis Plc Overview 5


Key Information 5


Key Facts 5


Vernalis Plc - Research and Development Overview 6


Key Therapeutic Areas 6


Vernalis Plc - Pipeline Review 8


Pipeline Products by Stage of Development 8


Pipeline Products - Monotherapy 9


Pipeline Products - Partnered Products 10


Partnered Products/Combination Treatment Modalities 11


Pipeline Products - Out-Licensed Products 12


Out-Licensed Products/Combination Treatment Modalities 13


Vernalis Plc - Pipeline Products Glance 14


Vernalis Plc - Clinical Stage Pipeline Products 14


Phase II Products/Combination Treatment Modalities 14


Vernalis Plc - Early Stage Pipeline Products 15


Preclinical Products/Combination Treatment Modalities 15


Discovery Products/Combination Treatment Modalities 16


Vernalis Plc - Unknown Stage Pipeline Products 17


Unknown Products/Combination Treatment Modalities 17


Vernalis Plc - Drug Profiles 18


V-81444 18


Product Description 18


Mechanism of Action 18


R&D Progress 18


CCP-05 19


Product Description 19


Mechanism of Action 19


R&D Progress 19


CCP-06 20


Product Description 20


Mechanism of Action 20


R&D Progress 20


V-158411 21


Product Description 21


Mechanism of Action 21


R&D Progress 21


vipadenant 22


Product Description 22


Mechanism of Action 22


R&D Progress 22


Small Molecule to Inhibit Chk1 for Cancer 23


Product Description 23


Mechanism of Action 23


R&D Progress 23


CCP-07 24


Product Description 24


Mechanism of Action 24


R&D Progress 24


CCP-08 25


Product Description 25


Mechanism of Action 25


R&D Progress 25


Vernalis Plc - Pipeline Analysis 26


Vernalis Plc - Pipeline Products by Target 26


Vernalis Plc - Pipeline Products by Route of Administration 27


Vernalis Plc - Pipeline Products by Molecule Type 28


Vernalis Plc - Pipeline Products by Mechanism of Action 29


Vernalis Plc - Recent Pipeline Updates 30


Vernalis Plc - Dormant Projects 32


Vernalis Plc - Discontinued Pipeline Products 33


Discontinued Pipeline Product Profiles 33


alfadolone 33


indantadol 33


marimastat 33


solimastat 33


V-1003 33


V-158866 34


vipadenant 34


Vernalis Plc - Company Statement 35


Vernalis Plc - Locations And Subsidiaries 37


Head Office 37


Other Locations & Subsidiaries 37


Appendix 38


Methodology 38


Coverage 38


Secondary Research 38


Primary Research 38


Expert Panel Validation 38


Contact Us 38


Disclaimer 39

Read More http://www.idatainsights.com/reports-landing-page.php?id=179162/vernalis-plc-product-pipeline-review-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.